ISOEUGENOL

US Approved Allergenic Extract (1994)

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2011/05/WC500106362.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/15606655
Curator's Comment: description was created based on several sources, including https://link.springer.com/article/10.1007/s00044-015-1486-6 | https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/isoeugenol_508.pdf | https://www.ncbi.nlm.nih.gov/pubmed/21995306

(E)-Isoeugenol is crystalline while compound with spice clove type odor. The melting point of E-isoeugenol is 33°C. E-Isoeugenol has been shown to cause contact and allergic dermatitis in humans. Positive skin patch tests in numerous individuals have confirmed the sensitizing ability of isoeugenol.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytosolic phospholipase A2 7 Target ID: CHEMBL3816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21995306	Inhibitor 8297
Tyrosyl-DNA phosphodiesterase 2 4 Target ID: CHEMBL2169736 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27220325	Inhibitor 8297
Cytochrome P450 1A1 31 Target ID: CHEMBL2231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22686307	Activator 1430
aryl-hydrocarbon receptor repressor 3 Target ID: 57491.0 Gene Symbol: AHRR Sources: https://www.ncbi.nlm.nih.gov/pubmed/22686307	Activator 1430
Transient receptor potential cation channel subfamily A member 1 38 Target ID: CHEMBL6007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18456404	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic contact dermatitis 14 Sources: http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM294327.pdf	Diagnostic		Approved 8429	TRUE Test Approved Use Unknown
Allergic contact dermatitis 14 Sources: http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM294327.pdf	Diagnostic		Approved 8429	TRUE Test Approved Use Fragrance mix is composed of eight substances, including isoeugenol (approximately 15 ug).

PubMed

Title	Date	PubMed
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.	2006 Nov	16497524
The mouse eugenol odorant receptor: structural and functional plasticity of a broadly tuned odorant binding pocket.	2011 Feb 8	21142015
Impact of eugenol and isoeugenol on AhR translocation, target gene expression, and proliferation in human HaCaT keratinocytes.	2012	22686307
In vitro activity of natural phenolic compounds against fluconazole-resistant Candida species: a quantitative structure-activity relationship analysis.	2014 Apr	24387763
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor.	2015 Mar 1	25617811

Patents

Sample Use Guides

In Vivo Use Guide

Isoeugenol is effective at low concentrations of 10 to 20 mg/L corresponding to active ingredient concentrations of 5 to 10 mg/L.

Route of Administration: Other

In Vitro Use Guide

Isoeugenol in low concentrations 206 uM caused a distinct decrease in twitch response in phrenic nerve-diaphragm preparations.

Name

Type

Language

ISOEUGENOL

Official Name

English

ISOEUGENOL [FHFI]

Common Name

English

4-HYDROXY-3-METHOXY-1-PROPENYLBENZENE

Common Name

English

2-METHOXY-4-(1-PROPENYL)PHENOL

Common Name

English

2-METHOXY-4-PROPENYLPHENOL

Common Name

English

ISOEUGENOL [FCC]

Common Name

English

FEMA NO. 2468

Code

English

ISOEUGENOL [INCI]

Common Name

English

ISOEUGENOL [USP-RS]

Common Name

English

ISOEUGENOL [MI]

Common Name

English

NSC-6769

Code

English

4-PROPENYLGUAIACOL

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN01AX94